MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
April 16, 2018
Via EDGAR
Correspondence Relating to Registration Statement
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: | Mary Beth Breslin |
Ada Sarmento |
RE: | MorphoSys AG (CIK No. 0001340243) |
Registration Statement on FormF-1 |
FileNo. 333-223843 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), MorphoSys AG (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement, as then amended, will be declared effective under the Securities Act at 4:00 p.m. Eastern Daylight Time on April 18, 2018, or as soon thereafter as is practicable.
We request that we be notified of such effectiveness by a telephone call to Stephan Hutter of Skadden, Arps, Slate, Meagher & Flom LLP at +49 69 7422 0170 and that such effectiveness also be confirmed in writing.
Very truly yours, | ||
MORPHOSYS AG | ||
/s/ Dr. Markus Enzelberger | ||
By: | Dr. Markus Enzelberger | |
Title: | Chief Scientific Officer | |
/s/ Isabelle Degbegni | ||
By: | Isabelle Degbegni | |
Title: | Senior Manager CFCD |
cc: | Skadden, Arps, Slate, Meagher & Flom (UK) LLP |
Stephan Hutter, Esq.
David J. Goldschmidt, Esq.